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Background: Hyponatremia occurring as a result of the syndrome of inappropriate antidiuretic hormone secretion
(SIADH) or cerebral salt wasting syndrome is a common complication in patients with subarachnoid hemorrhage
(SAH). The efficacy and safety of urea as treatment for SIADH-induced hyponatremia has not been reported in this
population.
Methods: This is a retrospective analysis of all patients admitted to our department for nontraumatic SAH between
January 2003 and December 2008 (n = 368). All patients with SIADH-induced hyponatremia (plasma
sodium< 135 mEq/L, urine sodium> 20 mEq/L, and osmolality > 200 mOsm/kg; absence of overt dehydration or
hypovolemia; no peripheral edema or renal failure; no history of adrenal or thyroid disease) routinely received urea
per os when hyponatremia was associated with clinical deterioration or remained less than 130 mEq/L despite
saline solution administration.
Results: Forty-two patients developed SIADH and were treated with urea. Urea was started after a median of 7
(IQR, 5–10) days and given orally at doses of 15–30 g tid or qid for a median of 5 (IQR, 3–7) days. The median
plasma sodium increase over the first day of treatment was 3 (IQR, 1–6) mEq/L. Hyponatremia was corrected in all
patients, with median times to Na+ >130 and >135 mEq/L of 1 (IQR, 1–2) and 3 (IQR, 2–4) days, respectively. Urea
was well tolerated, and no adverse effects were reported.
Conclusions: Oral urea is an effective and well-tolerated treatment for SIADH-induced hyponatremia in SAH
patients.
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Hyponatremia, defined as a plasma sodium concentra-
tion less than 135 mEq/L [1], is a common complication
in patients with subarachnoid hemorrhage (SAH) [2,3].
Hyponatremia associated with hypertonicity, e.g., be-
cause of hyperglycemia or mannitol therapy, does not
require any specific therapy in the absence of severe
neurological alterations. However, when hyponatremia is
associated with hypotonicity, the shift of water from the
extracellular to intracellular fluid can contribute to* Correspondence: ftaccone@ulb.ac.be
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in any medium, provided the original work is pworsening cerebral edema and intracranial hypertension,
promoting seizures and further compromising neuro-
logical recovery [4]. Thus, early diagnosis and effective
treatment of hyponatremia are crucial for patients with
SAH. In such patients, hypotonic hyponatremia often is
the result of the syndrome of inappropriate antidiuretic
hormone secretion (SIADH) [3,5,6]. The main differen-
tial diagnosis in this setting is with the cerebral salt
wasting syndrome (CSWS) [7,8], although the existence
of this syndrome is still debated [5,8,9].
SIADH is the result of excessive secretion of antidiure-
tic hormone (ADH) or ADH-like substances that cause
water retention. The resultant increased extracellular
fluid and increased blood volume cause water and
sodium diuresis, which reverse the blood volumes an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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SIADH is, therefore, best treated by restriction of water
intake to less than 500 ml/day, which can be difficult to
achieve in patients with SAH for several reasons. First,
many of these patients are unconscious and must be fed
enterally, which results in a fluid intake of 1–2 L daily;
second, hypovolemia must be avoided in patients with
SAH, because it is associated with an increased risk of
vasospasm and cerebral ischemia [11]. Therapeutic alter-
natives to water restriction include hypertonic solutions
and albumin, but their efficacy is controversial [1,10].
Vasopressin receptor antagonists have been proposed
[12,13], but they are expensive and can result in changes
in plasma sodium that are too rapid or excessive. An
easy and less expensive therapeutic option is the admin-
istration of urea [10,14]. Urea acts by inducing osmotic
water elimination and by promoting passive sodium re-
absorption in the ascending limb of the loop of Henle
[14]. Plasma sodium and tonicity increase progressively,
without causing hypertonicity. Reported adverse effects
have been limited to gastrointestinal discomfort. In our
department, we regularly use urea in acute SIADH oc-
curring after acute brain injury. We recently published a
retrospective review of urea use in a heterogeneous
population of intensive care unit (ICU) patients [15];
however, different causes of hyponatremia and nonstan-
dardized sodium administration were important con-
founding factors in the interpretation of these data. The
purpose of the present study was to describe the efficacy
and safety of urea for the treatment of acute SIADH in a
more homogeneous population of patients with nontrau-
matic SAH.
Methods
We reviewed the medical charts of 368 patients admitted
to our 35-bed Department of Intensive Care for non-
traumatic SAH during a 6-year period (January 2003 to
December 2008). All patients who developed hyponatre-
mia (Na <135 mEq/L) that persisted for more than 24
hours were evaluated for a diagnosis of SIADH as
defined by the following standard criteria [6]: a) plasma
sodium< 135 mEq /L, urine sodium> 20 mEq/L, and
urine osmolality > 200 mOsm/kg; b) no overt dehydra-
tion or peripheral edema; c) no renal failure, defined as a
serum creatinine ≤1.2 mg/dL; d) no previous history of
adrenal insufficiency, hypothyroidism, liver cirrhosis, or
heart failure [5]. We excluded patients with uncontrolled
hyperglycemia (>200 mg/dL) at the time of diagnosis
and patients treated with steroids, mannitol, or diuretics.
The study was approved by the institutional Ethics Com-
mittee (Comité d'Ethique Hospitalo-Facultaire Erasme-
ULB, reference number OM021), which waived the need
for informed consent. Patients treated with urea were
identified from the department database. No patientsincluded in a previous publication [15] were included in
the present cohort.
Our therapeutic protocol for SAH is standardized. All
patients typically receive 3 liters of saline solution (NaCl
0.9%) daily, with additional fluids for intravenous medi-
cations and enteral nutrition, if necessary. This strategy
is aimed at avoiding hypovolemia; no therapy associating
induced hypertension, hypervolemia, and hemodilution
(the so-called triple-H therapy) is initiated in the absence
of symptomatic vasospasm. If hyponatremia develops,
fluid intake is not restricted, but all intravenous fluids
(including those for drug administration) are changed to
isotonic saline. Hypertonic solutions or preventive
hydrocortisone are not used. Plasma sodium is moni-
tored at least every 12 hours. When SIADH is diag-
nosed, urea therapy is part of a standardized therapeutic
protocol in our ICU and is initiated when hyponatremia
is associated with clinical deterioration (defined as a re-
duction of at least 2 points in the Glasgow Coma Score
[GCS]) or remains < 130 mEq/L despite NaCl 0.9% ad-
ministration. Urea (Certa, Braine l’Alleud, Belgium) is
given as 15 to 30 g doses of a 99% pure crystalline prep-
aration, dissolved in 50 mL of water and administered
per os or by nasogastric tube. The dose is repeated every
6 or 8 hours in most patients, and occasionally every 4
hours with a maximum of 180 g per day. Patient man-
agement, including the indication for urea and its dose,
are discussed at least once daily with a senior ICU staff
member. Urea therapy is discontinued after at least 48
hours of sodium levels >135 mEq/L.
Data collection included patient demographics, World
Federation of Neurosurgeons Scale [16] and Fisher scale
[17] scores, the location and treatment of the aneurysm,
the urea doses, daily plasma and urine electrolytes and
urine osmolality, daily fluid balance, ICU, and hospital
lengths of stay and outcomes. Creatinine clearance
(CrCL) on admission was measured from urinary cre-
atinine excretion using the following formula: CrCL
(mL/min) = [daily urine output (mL) × urinary creatinine
(mg/dL)] / [urine output time collection (min) × serum
creatinine (mg/dL)]. Urea treatment efficacy was evalu-
ated as the time needed to restore safe (>130 mEq/L)
and normal (>135 mEq/L) plasma sodium levels. Over-
correction was defined as an increase in plasma sodium
>12 mEq/L during any 24-hour period [18]. We evalu-
ated potential adverse effects of urea therapy, including
gastrointestinal intolerance and excessive increases in
blood urea. In patients with altered consciousness,
gastrointestinal intolerance was defined as a gastric re-
sidual volume > 300 mL or repeated vomiting (>3/day),
developing during urea therapy. Excessive increase in
blood urea was defined as values > 80 mg/dL (normal
range, 15–40 mg/dL). Daily serum creatinine (sCr) levels
also were collected during urea therapy; renal dysfunction
Table 1 Patient characteristics
Age (yr) 56 ± 12



















Mechanical ventilation on admission, n (%) 30 (73)
ICU length of stay (days) 18 (12–25)
Hospital length of stay (days) 29 (21–35)
ICU mortality, n (%) 10 (23)
Hospital mortality, n (%) 11 (26)
Data are expressed as counts (percentage), median (IQR) or mean± SD.
WFNS World Federation Neurosurgeon Scale, ICU Intensive care unit.
Table 2 Sodium values and urea use
Plasma Na at admission (mEq/L) 139± 3
Plasma Na at diagnosis of hyponatremia (mEq/L) 131± 2
Days from admission to diagnosis of hyponatremia 4 (2–5)
Plasma Na before urea (mEq/L) 127± 2
Days from admission to start of urea treatment 7 (5–10)
Duration of urea treatment (days) 5 (3–7)
Daily urea dose (g/day) 50 (40–60)
Change in plasma Na over first 24 h (mEq/L) 3 (1–6)
Time to plasma Na> 130 mEq/L (days) (n = 25) 1 (1–2)
Time to plasma Na> 135 mEq/L (days) (n = 42) 3 (2–4)
Data are expressed as median (IQR) or mean (±SD).
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compared with baseline levels. We also recorded the oc-
currence of sepsis and heart failure during the ICU stay,
because these conditions may complicate hyponatremia.
Finally, we recorded arterial lactate (normal range,
<2 mEq/L) and central venous pressure (CVP) levels
daily; the need for fluid and vasopressor administration
for reasons other than vasospasm was considered as a
possible indicator of hypovolemia. Long-term follow-up
was retrospectively assessed by using the Glasgow Out-
come Scale (GOS: 1 =Dead; 2 =Vegetative State; 3 = Se-
verely Disabled; 4 =Moderately Disabled; 5 =Good
Recovery) from the medical charts of the 6-month
(±2 weeks) neurosurgical visit.
Statistical analyses were performed by using the SPSS
13.0 package. Discrete variables were compared by
chi-square or Fisher’s exact tests. Normally distributed
continuous variables were expressed as mean± SD and
compared by Student’s t tests. Other continuous vari-
ables were expressed as median (25th – 75th percentiles)
and compared by Mann–Whitney tests. Repeated mea-
sures ANOVA for groups per time interaction and
group and time comparisons, with Bonferroni correc-
tion for post hoc analysis, was used. Linear correlation
was calculated using Spearman correlation coefficient. A
p value < 0.05 was considered statistically significant.
Results
Among 368 patients with SAH during the study period,
100 patients (27%) developed hyponatremia for more
than 24 hours. Forty-two patients met the diagnostic cri-
teria for SIADH and received urea. The characteristics
of these patients are shown in Table 1. Almost all
patients were scored grade III or IV on the Fisher scale,
and 37 patients had an aneurysm explaining the SAH.
At ICU admission, 41 patients had a normal sodium
concentration. Hyponatremia was diagnosed after a me-
dian of 4 days (Table 2). All patients had a positive fluid
balance over the 48 hours preceding urea administration
(Table 3). None of these patients developed sepsis, renal,
or heart failure during their ICU stay.
Urea was started after a median of 7 days, given for a
median of 5 days, and discontinued in all patients before
ICU discharge. Urea was generally given in 15 or 30 g
doses tid or qid, with a median daily dose of 50 g. Most
patients (31/42) received urea through a nasogastric
tube. Hyponatremia was reversed in all patients, with
plasma sodium returning to greater than 130 and
135 mEq/l after median times of 1 and 3 days, respect-
ively. Plasma sodium increased by a median of 3 (IQR,
1–6) and 5 (IQR, 3–10) mEq/L over the first and second
days of treatment, respectively (Figure 1).
Arterial lactate levels remained within normal ranges,
and the CVP was > 5 mmHg in all patients; no signs ofhypovolemia were noted before or during urea therapy.
Compared with the day before the start of urea, urine
output increased during the first day of therapy, despite
a similar fluid intake (Table 3). Urine osmolality and
urine urea concentrations also increased, whereas urine
sodium decreased. There was an inverse correlation
Table 3 Sodium and volume balance before (day −2 and day −1) and after (day 1 and day 2) the onset of urea therapy
Variable Day −2 Day −1 Day 1 Day 2 After urea
Fluid intake (mL/24 hr) 4411 ± 1149 3958± 1348 3784± 1090 3875± 1370 2567± 1370
Urine output (mL/24 hr) 3886 ± 1842 3757± 1174 4288± 1472 4296± 1692a 1879 ± 489
Na intake (mEq/24 hr) 349 ± 181 375 ± 171 350 ± 161 346 ± 193 141± 69
Urine Na (mEq/24 hr) 520 ± 244 521 ± 262 467 ± 256a,b 491 ± 355 78 ± 36
Urine osmolality (mOsm/Kg) 515 ± 164 498 ± 125 578 ± 119 611 ± 134b 418± 96
Serum urea (mg/dL) 30 ± 9 30 ± 6 39 ± 11a,b 37 ± 10a,b 31 ± 6
Urine urea (mg/dL) 632 ± 319 699 ± 418 1653± 677a,b 1894 ± 455a,b 788± 401
“After urea” shows data on the fifth day after urea discontinuation (n = 34). Data are presented as mean ± SD. ANOVA analysis for urine output: p= 0.048. ANOVA
analysis for urin osmolality: p= 0.005. ANOVA analysis for urine Na: p= 0.04. ANOVA analysis for serum urea: p< 0.001. P value < 0.05 vs. day −2 (a), day −1 (b), or
day 1 (c) in post-hoc Bonferroni correction.
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sodium during the first 24 hours of urea administration
(Figure 2). There was no correlation between baseline
plasma sodium or CrCL and change in plasma sodium.
Urea was well tolerated and no gastrointestinal, or
hemodynamic adverse effects were reported. No renal
dysfunction was observed during urea therapy. The
plasma sodium increased ≥12 mEq/L during the first
day of therapy in four patients, but no clinical deterior-
ation was observed. Two patients developed transient
hypernatremia (maximum value 149 mEq/L), which
resolved within 24 hours. Sodium concentrations
remained greater than 135 mEq/L in patients with so-
dium measurements available on the fifth day after urea
discontinuation (Table 3; Figure 1), whereas urine osmo-
lality, sodium, and urea concentrations progressivelyFigure 1 Plasma sodium (mEq/L) at baseline (before therapy)
and on days 1, 2, and 3 of urea therapy and on the fifth day
after urea discontinuation (post-urea). ANOVA analysis (excluding
the last time point) for sodium changes over time –= p= 0.001.
* = p< 0.01 vs. baseline, $ = p< 0.01 vs. day 1 in post-hoc Bonferroni
correction.decreased. No patient had blood urea levels greater than
80 mg/dL during the treatment period.
There were no differences between ICU survivors and
nonsurvivors for admission sodium levels (139 ± 3 vs.
141 ± 4 mEq/L) or in the lowest sodium levels reached
during the ICU stay (127 ± 3 vs. 128 ± 2 mEq/L). The
GOS at 6 months was one in 23 patients, two in 5
patients, and three in 3 patients; among the 4 patients
who had overcorrection of their natremia, 3 had a GOS
of 1 and 1 patient, whose GOS was 2 during hospital
stay, died of massive pulmonary embolism 1 month after
SAH occurrence.
Discussion
Our results show for the first time that urea is an effective
and safe treatment for hyponatremia in patients who de-
velop SIADH and persistent hyponatremia after SAH.
Most of the patients in our cohort had a poor radiological
score (Fisher III or IV) and half of them had a poor neuro-
logical status (WFNS≥ 3) on admission. Importantly, fluid
and sodium administration were standardized (only NaCl
0.9% was administered and other potential therapies to re-
verse hyponatremia were not used), and negative fluid bal-
ance, fluid restriction, and diuretic therapy were avoided
in all cases. The diagnosis of SIADH was made by using
well-established criteria [6]. We did not routinely measure
blood volume, but none of our patients had clinical or bio-
logical signs of hypovolemia or tissue hypoperfusion sug-
gesting a diagnosis of CSWS.
Urea was given after saline solutions failed to prevent
or reverse the hyponatremia. In these conditions of per-
sisting hyponatremia, urea restored normal sodium
levels within 3 days in half of the patients; 5 patients
needed more than 5 days of therapy to restore sodium
levels >135 mEq/L, but there were no urea “nonrespon-
ders” in the present series. In clinical practice, what
represents significant hyponatremia is not clearly defined
[1]. The lower limit of the normal range is 135 mEq/L,
and SAH patients with sodium levels below this thresh-
old have a worse outcome [19,20]; however, mild
Figure 2 Relationship between baseline urine osmolality (mOsm/Kg) and change in plasma sodium (DeltaNa, mEq/L) during the first
24 hours of urea therapy.
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treatment often is recommended only when the plasma
sodium decreases below 130 mEq/L. We, therefore,
defined two therapeutic endpoint values, 130 and
135 mEq/L, which were reached after a median of 1 and
3 days, respectively. The time to correction may seem
longer than seen with other therapies [13], but the dur-
ation of hyponatremia before treatment was approxi-
mately 3 days, and the risks of osmotic demyelination
would have been significant with quicker correction
rates. Although the optimal rate of plasma sodium cor-
rection in acute hyponatremia has not been clearly
defined, it is generally agreed that increases ≥12 mEq/L
during 24 hours must be avoided [18,21]. In the present
study, few overcorrections were observed, and none of
the patients whose plasma sodium increased ≥12 mEq/L
during the first day had long-term neurological impair-
ment. Rates of overcorrection rarely have been reported
in previous studies on hyponatremia therapy during
SAH; only 1 of 41 patients treated with conivaptan had
sodium overcorrection during therapy [12,13]. The pro-
gressive increase in plasma sodium levels, in contrast
with the sharp increases sometimes reached when other
therapies are used, may help to limit clinical complica-
tions. Moreover, experimental data suggest the concept
that urea has a protective effect against the osmotic de-
myelination syndrome [22].
Urea increased renal water excretion due to osmotic
diuresis and reduced urinary sodium loss. Constant fluid
intake was maintained in all patients, and excess water
was eliminated without noticeable arterial hypotension.
This approach seems to represent a better option than
fluid restriction, with potential complications of delayedcerebral infarcts in these patients at high risk of vaso-
spasm. Importantly, there were no adverse effects. Urea
is rapidly absorbed from the gastrointestinal tract [22,23]
and may cause gastric discomfort [14]; however, most
patients received the urea though a nasogastric tube,
without adverse events. Blood urea levels increased only
moderately during therapy, and this is consistent with
increased urinary urea excretion, ultimately resulting in
effective osmotic water excretion.
This study was not designed to identify the optimal
strategy or most appropriate dose of urea therapy. How-
ever, the response to urea was not correlated with base-
line plasma sodium, suggesting that urea is effective
even in mild hyponatremia. In contrast, there was an in-
verse correlation between baseline urine osmolality and
the rate of plasma sodium correction, suggesting that
the higher the urine osmolality, the lower the ability of
urea at the doses used to induce a rapid osmotic diuresis
and to reverse hyponatremia. A similar finding has been
reported in other studies and has been attributed to a
reduced ability to excrete the excessive water when urine
osmolality is high [24].
Alternative therapeutic options for preventing or revers-
ing hyponatremia in neurocritical patients include albu-
min, fludrocortisone, hypertonic saline, and vasopressin
receptor antagonists, such as conivaptan. The effects of al-
bumin in limiting natriuresis have been reported in only
one study [25], and they remain controversial [26]. Fludro-
cortisone enhances sodium retention through its min-
eralocorticoid properties, but its ability to correct
hyponatremia is limited and it contributes to fluid over-
load [27,28]. Hypertonic saline solutions can increase
plasma sodium concentration efficiently and very rapidly,
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monary edema and heart failure as well as of neurological
complications. Their effects are generally transient
because the stimuli for water retention and secondary
natriuresis remain present [29]. Vasopressin receptor
antagonists represent a promising option, and conivaptan
has been studied in two series of neurointensive care
patients. In one study, a single dose of 20 mg of conivap-
tan increased plasma sodium by at least 4 mEq/L in 13 of
19 hyponatremic patients and maintained the sodium im-
provement for 3 days in most of the patients [12]. In an-
other study, conivaptan increased plasma sodium by at
least 6 mEq/L in 19 of 22 euvolemic hyponatremic
patients and maintained its effects for an average of 13
hours [13]. However, the studies included only 12 patients
with SAH, and fludrocortisone or hypertonic saline also
were given in some patients. Moreover, conivaptan often
was limited to a single bolus, and a third of the patients
became hyponatremic when conivaptan was discontinued.
Practical limitations to vasopressin receptor antagonists
include the costs of the drug and the unpredictability of
the response amplitude and duration [1]. Diuretics can be
used to induce osmotic diuresis; however, they are likely
to induce hypovolemia in this setting, with an increased
risk of delayed cerebral ischemia [10]. Finally, demeclocy-
cline can reverse hyponatremia induced by SIADH, but
several adverse events, including nephrotoxicity, have
been reported [30].
Our study has some limitations. First, the retrospective
nature of the study may have limited the collection of per-
tinent clinical or biological data, such as adverse events.
Second, we did not specifically record the neurological
status or intracranial pressure according to plasma sodium
values, so that the relationship between sodium changes
and clinical changes cannot be evaluated. Also, we did not
measure plasma osmolality. Third, no specific protocol
was used for urea administration, and regimen changes
were at the physician’s discretion, therefore, the optimal
dose of urea and its impact on sodium level changes can-
not be determined. Fourth, we specifically studied SAH
patients, and our findings can be extended to other
patients only with caution. Fifth, the purpose of this study
was not to evaluate all the different pathophysiological
mechanisms that underlie hyponatremia after acute brain
injury, and no specific conclusions can be made about the
effects of urea in other conditions associated with sodium
imbalance in this setting. Sixth, we consider the serum
urea levels reached (<80 mg/dL) to be safe, because most
of the complications related to uremia occur with urea
concentrations >200 mg/dL; however, we cannot exclude
that complications may arise at lower urea levels. Finally,
the efficacy of urea compared with other available treat-
ments needs to be determined in large, prospective
studies.Conclusions
Urea is an effective treatment for SIADH-related hypo-
natremia in patients with SAH. It is generally well-
tolerated and can help to avoid fluid restriction. Dose
titration and plasma sodium response rate should be fur-
ther studied prospectively. Also, the efficacy of urea
therapy compared with other drugs, such as albumin,
hydrocortisone, hypertonic saline solution, and vasopres-
sin receptor antagonists, remains to be demonstrated.
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